APP and Alzheimer disease: To further address the effect of early treatment of CC on Alzheimer's disease symptoms and Aβ pathology, 3-month-old APP/PS1 mice were treated with CC (7 mg/kg) every 3 days to 8 months of age (Fig. 5A).